Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : in talks with FDA on Alzheimer's candidate, says CEO

07/22/2021 | 03:09am EDT

ZURICH, July 22 (Reuters) - Swiss drugmaker Roche is discussing its potential treatment for Alzheimer's disease with the U.S. Food and Drug Administration (FDA) as clinical trials proceed, Chief Executive Severin Schwan told reporters on Thursday.

Analysts have speculated about an expedited filing for regulatory approval of gantenerumab, which could be a blockbuster if shown to work against the debilitating disease.

Roche will complete a Phase-III trial of the medicine in the second half of next year, Schwan said, citing the urgency of finding a way to treat such an unmet medical need and bringing it to patients as soon as possible.

"There is a continued dialogue with the FDA. I wouldn't be able to speculate what the outcome of this dialogue will be," he said.

"Our trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let's keep fingers crossed," he added.

(Reporting by Michael Shields; Editing by Edmund Blair)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CREDIT SUISSE GROUP AG -0.04% 9.504 Delayed Quote.-16.63%
ROCHE HOLDING AG -0.65% 342.9 Delayed Quote.10.97%
All news about ROCHE HOLDING AG
09/17ROCHE : European Medicines Agency Recommends Roche's Lung Cancer Drug For Approv..
MT
09/17ROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
MD
09/17ROCHE : receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatm..
AQ
09/17PRESS RELEASE : Roche receives positive CHMP -2-
DJ
09/17PRESS RELEASE : Roche receives positive CHMP opinion for Gavreto(R) (pralsetinib..
DJ
09/17ROCHE : Drug Halts Tumor Proliferation in Mid-Stage Breast Cancer Study
MT
09/17ROCHE : presents first phase II data on giredestrant, a next generation selectiv..
PU
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/15ROCHE HOLDINGS AG : Receives a Buy rating from Deutsche Bank
MD
09/15ROCHE HOLDINGS AG : JP Morgan reaffirms its Neutral rating
MD
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 302 M 65 734 M 65 734 M
Net income 2021 14 713 M 15 777 M 15 777 M
Net cash 2021 4 891 M 5 244 M 5 244 M
P/E ratio 2021 19,6x
Yield 2021 2,74%
Capitalization 299 B 321 B 321 B
EV / Sales 2021 4,80x
EV / Sales 2022 4,66x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 342,90 CHF
Average target price 384,23 CHF
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG10.97%321 442
JOHNSON & JOHNSON4.68%433 701
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604
ABBVIE INC.0.54%190 378